Answer
Breastfeeding should be discontinued throughout ramucirumab (Cyramza) treatment and for at least 3 months after the last dose because a risk to breastfed newborns or infants cannot be excluded.
Sources for this answer
- Cyramza 10 mg/ml concentrate for solution for infusionEli Lilly and Company Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 18Document updated
Sources checked